Review article: a comparison of glucagon-like peptides 1 and 2. (Q38057350)

27 August 2017

title

Review article: a comparison of glucagon-like peptides 1 and 2. (English)

1 reference

27 August 2017

1 reference

P Janssen

1

1 reference

27 August 2017

A Rotondo

series ordinal

2

1 reference

27 August 2017

F Mulé

series ordinal

3

1 reference

27 August 2017

J Tack

series ordinal

4

1 reference

27 August 2017

language of work or name

English

0 references

publication date

5 November 2012

1 reference

Alimentary Pharmacology & Therapeutics

27 August 2017

published in

1 reference

27 August 2017

volume

37

1 reference

27 August 2017

issue

1

1 reference

27 August 2017

page(s)

18-36

1 reference

Clinical endocrinology and metabolism. Glucagon-like peptide-1 and glucagon-like peptide-2.

27 August 2017

cites work

1 reference

The Physiology of Glucagon-like Peptide 1

21 January 2018

1 reference

Enhancing Incretin Action for the Treatment of Type 2 Diabetes

21 January 2018

1 reference

21 January 2018

Glucagon-like Peptide-2.

1 reference

The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease

21 January 2018

1 reference

Review article: glucagon-like peptide 2--current applications and future directions

21 January 2018

1 reference

Proglucagon gene expression is regulated by a cyclic AMP-dependent pathway in rat intestine

21 January 2018

1 reference

Role of the prohormone convertase PC3 in the processing of proglucagon to glucagon-like peptide 1.

21 January 2018

1 reference

Impaired intestinal proglucagon processing in mice lacking prohormone convertase 1.

21 January 2018

1 reference

Improving function and survival of pancreatic islets by endogenous production of glucagon-like peptide 1 (GLP-1).

21 January 2018

1 reference

Disruption of PC1/3 expression in mice causes dwarfism and multiple neuroendocrine peptide processing defects

21 January 2018

1 reference

The glucagon-like peptides: pleiotropic regulators of nutrient homeostasis

21 January 2018

1 reference

Glucagon-like peptide-1 and glucose-dependent insulin-releasing polypeptide plasma levels in response to nutrients

21 January 2018

1 reference

Rapid tachyphylaxis of the glucagon-like peptide 1-induced deceleration of gastric emptying in humans

21 January 2018

1 reference

Gastrointestinal regulation of food intake

21 January 2018

1 reference

Glucose-sensing in glucagon-like peptide-1-secreting cells

21 January 2018

1 reference

Muscarinic receptors control glucagon-like peptide 1 secretion by human endocrine L cells

21 January 2018

1 reference

Regulation of Intestinal Proglucagon- Derived Peptide Secretion by Intestinal Regulatory Peptides*

21 January 2018

1 reference

Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo

21 January 2018

1 reference

Secretion, degradation, and elimination of glucagon-like peptide 1 and gastric inhibitory polypeptide in patients with chronic renal insufficiency and healthy control subjects

21 January 2018

1 reference

Short bowel syndrome: the role of GLP-2 on improving outcome.

21 January 2018

1 reference

Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2

21 January 2018

1 reference

Biology of incretins: GLP-1 and GIP

21 January 2018

1 reference

Functional expression of the rat glucagon-like peptide-I receptor, evidence for coupling to both adenylyl cyclase and phospholipase-C.

21 January 2018

1 reference

Divergent tissue-specific and developmental expression of receptors for glucagon and glucagon-like peptide-1 in the mouse

21 January 2018

1 reference

Expression of the GLP-1 receptor in mouse, rat, and human pancreas

21 January 2018

1 reference

Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells

21 January 2018

1 reference

Peripheral motor action of glucagon-like peptide-1 through enteric neuronal receptors

21 January 2018

1 reference

Receptor-mediated activation of gastric vagal afferents by glucagon-like peptide-1 in the rat.

21 January 2018

1 reference

Enteroendocrine localization of GLP-2 receptor expression in humans and rodents

21 January 2018

1 reference

Receptor identification and physiological characterisation of glucagon-like peptide-2 in the rat heart.

21 January 2018

1 reference

Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling

21 January 2018

1 reference

Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells

21 January 2018

1 reference

Modulation of specific intestinal epithelial progenitors by enteric neurons

21 January 2018

1 reference

GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors

21 January 2018

1 reference

Role of cholinergic neurons in the motor effects of glucagon-like peptide-2 in mouse colon.

21 January 2018

1 reference

Proglucagon-derived peptides: mechanisms of action and therapeutic potential

21 January 2018

1 reference

GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow

21 January 2018

1 reference

GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1.

21 January 2018

1 reference

Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I.

21 January 2018

1 reference

Enteral nutrients potentiate the intestinotrophic action of glucagon-like peptide-2 in association with increased insulin-like growth factor-I responses in rats

21 January 2018

1 reference

Insulin-like growth factor I and glucagon-like peptide-2 responses to fasting followed by controlled or ad libitum refeeding in rats.

21 January 2018

1 reference

ErbB activity links the glucagon-like peptide-2 receptor to refeeding-induced adaptation in the murine small bowel.

21 January 2018

1 reference

ErbB signaling is required for the proliferative actions of GLP-2 in the murine gut.

21 January 2018

1 reference

Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2.

21 January 2018

1 reference

Glucagon-like peptide-2 relaxes mouse stomach through vasoactive intestinal peptide release.

21 January 2018

1 reference

Frontiers in glucagon-like peptide-2: multiple actions, multiple mediators

21 January 2018

1 reference

The "cryptic" mechanism of action of glucagon-like peptide-2.

21 January 2018

1 reference

Ontogeny of the glucagon-like peptide-2 receptor axis in the developing rat intestine.

21 January 2018

1 reference

GLP-2 levels in infants with intestinal dysfunction

21 January 2018

1 reference

Functional ontogeny of the proglucagon-derived peptide axis in the premature human neonate.

21 January 2018

1 reference

Tissue and plasma concentrations of amidated and glycine-extended glucagon-like peptide I in humans

21 January 2018

1 reference

Insulinotropic hormone glucagon-like peptide-I(7-37) stimulation of proinsulin gene expression and proinsulin biosynthesis in insulinoma beta TC-1 cells

21 January 2018

1 reference

Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach.

21 January 2018

1 reference

Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans

21 January 2018

1 reference

Glucagon-like peptide-1: a potent regulator of food intake in humans

21 January 2018

1 reference

Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men.

21 January 2018

1 reference

A meta-analysis of the effect of glucagon-like peptide-1 (7-36) amide on ad libitum energy intake in humans

21 January 2018

1 reference

The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation

21 January 2018

1 reference

Local, exendin-(9-39)-insensitive, site of action of GLP-1 in canine ileum

21 January 2018

1 reference

Glucagonlike peptide-1 (GLP-1) participation in ileal brake induced by intraluminal peptones in rat.

21 January 2018

1 reference

Distinct effects of glucose-dependent insulinotropic polypeptide and glucagon-like peptide-1 on insulin secretion and gut motility

21 January 2018

1 reference

Effects of glucagon-like peptide-1(7-36)amide on motility and sensation of the proximal stomach in humans

21 January 2018

1 reference

Inhibitory effect of glucagon-like peptide-1 on small bowel motility. Fasting but not fed motility inhibited via nitric oxide independently of insulin and somatostatin

21 January 2018

1 reference

Effects of GLP-1 on gastric emptying, antropyloric motility, and transpyloric flow in response to a nonnutrient liquid

21 January 2018

1 reference

Glucagon-like peptide-1 relaxes gastric antrum through nitric oxide in mice.

21 January 2018

1 reference

Relation between gastric emptying of glucose and plasma concentrations of glucagon-like peptide-1.

21 January 2018

1 reference

Effect of exenatide on gastric emptying and relationship to postprandial glycemia in type 2 diabetes

21 January 2018

1 reference

Nitrergic contribution to gastric relaxation induced by glucagon-like peptide-1 (GLP-1) in healthy adults.

21 January 2018

1 reference

Effects of glucagon-like peptide-1 and sympathetic stimulation on gastric accommodation in humans

21 January 2018

1 reference

GLP-1 inhibits gastric emptying of water but does not influence plasma

21 January 2018

1 reference

Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets

21 January 2018

1 reference

Glucagon-like peptide 1 induces differentiation of islet duodenal homeobox-1-positive pancreatic ductal cells into insulin-secreting cells

21 January 2018

1 reference

Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo

21 January 2018

1 reference

GLP-1 derivative liraglutide in rats with beta-cell deficiencies: influence of metabolic state on beta-cell mass dynamics

21 January 2018

1 reference

Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats

21 January 2018

1 reference

Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage

21 January 2018

1 reference

A novel GLP-1 analog exhibits potent utility in the treatment of type 2 diabetes with an extended half-life and efficient glucose clearance in vivo

21 January 2018

1 reference

Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis

21 January 2018

1 reference

Activation of the GLP-1 receptor signalling pathway: a relevant strategy to repair a deficient beta-cell mass

21 January 2018

1 reference

An overview of once-weekly glucagon-like peptide-1 receptor agonists--available efficacy and safety data and perspectives for the future.

21 January 2018

1 reference

The role of incretins in salt-sensitive hypertension: the potential use of dipeptidyl peptidase-IV inhibitors

21 January 2018

1 reference

The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea

21 January 2018

1 reference

Efficacy and safety of the human glucagon-like peptide-1 analog liraglutide in combination with metformin and thiazolidinedione in patients with type 2 diabetes (LEAD-4 Met+TZD).

21 January 2018

1 reference

Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes

21 January 2018

1 reference

Safety, efficacy and tolerability of exenatide in combination with insulin in the Association of British Clinical Diabetologists nationwide exenatide audit*.

21 January 2018

1 reference

Efficacy of the glucagon-like peptide-1 agonist exenatide in the treatment of short bowel syndrome

21 January 2018

1 reference

Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

21 January 2018

1 reference

Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial

21 January 2018

1 reference

Potent derivatives of glucagon-like peptide-1 with pharmacokinetic properties suitable for once daily administration

21 January 2018

1 reference

Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU)

21 January 2018

1 reference

Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study

21 January 2018

1 reference

Weighing risks and benefits of liraglutide--the FDA's review of a new antidiabetic therapy

21 January 2018

1 reference

Obesity and treatment of diabetes with glyburide may both be risk factors for acute pancreatitis

21 January 2018

1 reference

Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons

21 January 2018

1 reference

Glucagon-like peptide 1 can directly protect the heart against ischemia/reperfusion injury

21 January 2018

1 reference

Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy

21 January 2018

1 reference

Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease.

21 January 2018

1 reference

Induction of intestinal epithelial proliferation by glucagon-like peptide 2.

21 January 2018

1 reference

Glucagon-like peptide-2 modulates neurally evoked mucosal chloride secretion in guinea pig small intestine in vitro

21 January 2018

1 reference

The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist

21 January 2018

1 reference

The role of incretins in glucose homeostasis and diabetes treatment

21 January 2018

1 reference

Mechanism of action of glucagon-like peptide-2 to increase IGF-I mRNA in intestinal subepithelial fibroblasts

21 January 2018

1 reference

The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon-like peptide-2 in mice

21 January 2018

1 reference

Exogenous glucagon-like peptide-2 (GLP-2) augments GLP-2 receptor mRNA and maintains proglucagon mRNA levels in resected rats

21 January 2018

1 reference

Sustained glucagon-like peptide-2 infusion is required for intestinal adaptation, and cessation reverses increased cellularity in rats with intestinal failure

21 January 2018

1 reference

Nutrient-stimulated GLP-2 release and crypt cell proliferation in experimental short bowel syndrome.

21 January 2018

1 reference

Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice.

21 January 2018

1 reference

Elevated plasma glucagon-like peptide 1 and 2 concentrations in ileum resected short bowel patients with a preserved colon.

21 January 2018

1 reference

Plasma concentrations of glucagon-like peptide-2 in adult patients with treated and untreated coeliac disease

21 January 2018

1 reference

Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome

21 January 2018

1 reference

Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon.

21 January 2018

1 reference

Teduglutide (ALX-0600), a dipeptidyl peptidase IV resistant glucagon-like peptide 2 analogue, improves intestinal function in short bowel syndrome patients

21 January 2018

1 reference

Impaired meal stimulated glucagon-like peptide 2 response in ileal resected short bowel patients with intestinal failure.

21 January 2018

1 reference

Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse

21 January 2018

1 reference

Stress impairs murine intestinal barrier function: improvement by glucagon-like peptide-2.

21 January 2018

1 reference

Glucagon-like peptide-2 reduces intestinal permeability but does not modify the onset of type 1 diabetes in the nonobese diabetic mouse.

21 January 2018

1 reference

Changes in gut microbiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability

21 January 2018

1 reference

Glucagon-like peptide-2 increases intestinal lipid absorption and chylomicron production via CD36.

21 January 2018

1 reference

Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans

21 January 2018

1 reference

Rapid insertion of GLUT2 into the rat jejunal brush-border membrane promoted by glucagon-like peptide 2

21 January 2018

1 reference

Glucagon-like peptide 2 enhances maltase-glucoamylase and sucrase-isomaltase gene expression and activity in parenterally fed premature neonatal piglets

21 January 2018

1 reference

Glucagon-like peptide-2 acutely increases proximal small intestinal blood flow in TPN-fed neonatal piglets

21 January 2018

1 reference

Glucagon-like peptide-2 increases mesenteric blood flow in humans.

21 January 2018

1 reference

Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2.

21 January 2018

1 reference

Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1.

21 January 2018

1 reference

The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake.

21 January 2018

1 reference

Role of glial cell-line derived neurotropic factor family receptor alpha2 in the actions of the glucagon-like peptides on the murine intestine

21 January 2018

1 reference

Preproglucagon derived peptides GLP-1, GLP-2 and oxyntomodulin in the CNS: role of peripherally secreted and centrally produced peptides

21 January 2018

1 reference

Synergistic effect of glucagon-like peptide 2 (GLP-2) and of key growth factors on the proliferation of cultured rat astrocytes. Evidence for reciprocal upregulation of the mRNAs for GLP-2 and IGF-I receptors

21 January 2018

1 reference

Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes

21 January 2018

1 reference

Glucagon-like peptides 1 and 2 and vasoactive intestinal peptide are neuroprotective on cultured and mast cell co-cultured rat myenteric neurons

21 January 2018

1 reference

Antidepressant-like effects of glucagon-like peptide-2 in mice occur via monoamine pathways.

21 January 2018

1 reference

Comparative effects of glucagon-like peptide-2 (GLP-2), growth hormone (GH), and keratinocyte growth factor (KGF) on markers of gut adaptation after massive small bowel resection in rats.

21 January 2018

1 reference

The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight

21 January 2018

1 reference

Teduglutide, a novel mucosally active analog of glucagon-like peptide-2 (GLP-2) for the treatment of moderate to severe Crohn's disease

21 January 2018

1 reference

Randomised placebo-controlled trial of teduglutide in reducing parenteral nutrition and/or intravenous fluid requirements in patients with short bowel syndrome

21 January 2018

1 reference

The HeLa cell glucagon-like peptide-2 receptor is coupled to regulation of apoptosis and ERK1/2 activation through divergent signaling pathways

21 January 2018

1 reference

Does glucagon like peptide-2 receptor expression have any effect on the development of human colorectal cancer?

21 January 2018

1 reference

Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice.

21 January 2018

1 reference

Glucagon-like peptide-2 does not modify the growth or survival of murine or human intestinal tumor cells

21 January 2018

1 reference

Glucagon-like peptide-2 increases dysplasia in rodent models of colon cancer

21 January 2018

1 reference

Loss of glucagon-like peptide-2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion.

21 January 2018

1 reference

Emerging treatment options for short bowel syndrome: potential role of teduglutide

21 January 2018

1 reference

Exenatide may aggravate moderate diabetic renal impairment: a case report

21 January 2018

1 reference

Localization and Activation of Glucagon-Like Peptide-2 Receptors on Vagal Afferents in the Rat

21 January 2018

1 reference

Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression1This work was supported by a grant from the Crohn's and Colitis Foundation of America.1

21 January 2018

1 reference

Glucagon-Like Peptides GLP-1 and GLP-2, Predicted Products of the Glucagon Gene, Are Secreted Separately from Pig Small Intestine but Not Pancreas*

21 January 2018

1 reference

Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms

21 January 2018

1 reference

Glucagon-Like Peptide-2 Inhibits Centrally Induced Antral Motility in Pigs

21 January 2018

1 reference

Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety

21 January 2018

1 reference

No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1111/APT.12092

1 reference

27 August 2017

1 reference